Patents Examined by Timothy R Rozof
  • Patent number: 10633392
    Abstract: The present invention provides unified synthesis of the CI-CI 9 building blocks of halichondrins and analogs thereof using selective coupling of poly-halogenated nucleophiles in chromium-mediated coupling reactions. The present invention also provides a practical and efficient synthesis of C20-C38 building blocks of halichondrins and analogs thereof. Also provided herein are general methods of selective activation and coupling of poly-halogenated analogs with an aldehyde. The provided coupling reactions are selective for halo-enone and halo-acetylenic ketal over vinyl halide and halide attached to a sp hydridized carbon. The provided efficient selective coupling reactions can allow easy access to the CI-CI 9 building blocks and C20-C38 building blocks of halichondrins and analogs thereof with limited or no purification or separation of the intermediates.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: April 28, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Yoshito Kishi, Wuming Yan, Jingwei Li, Zhanjie Li, Kenzo Yahata
  • Patent number: 10633390
    Abstract: The present invention relates to an improved process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl ester compound of formula-1 represented by the following structural formula:
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: April 28, 2020
    Assignee: MSN LABORATORIES PRIVATE LIMITED
    Inventors: Srinivasan Thirumalai Rajan, Sajja Eswaraiah, Revu Satyanarayana
  • Patent number: 10624883
    Abstract: A problem to be solved by the present invention is to provide a novel preventive or therapeutic agent for pulmonary hypertension containing as an active ingredient a compound that has not been known for a therapeutic effect on pulmonary hypertension heretofore. The present invention provides a preventive or therapeutic agent for pulmonary hypertension containing an ingredient having a selenoprotein P activity-inhibiting action.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: April 21, 2020
    Assignee: TOHOKU UNIVERSITY
    Inventors: Hiroaki Shimokawa, Kimio Satoh, Nobuhiro Kikuchi
  • Patent number: 10618882
    Abstract: A compound represented by formula (I), wherein A? represents a halogen ion, a benzenesulfonate ion, an alkylsulfonate ion or the like, X represents a halogeno group or the like, a is an integer of 0 to 4, Y represents a C1-C8 alkyl group or the like, b is an integer of 0 to 5.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: April 14, 2020
    Assignee: Nippon Soda Co., Ltd.
    Inventors: Yuki Hashimoto, Katsumi Okada, Fuminori Komatsu, Satoshi Kajita, Tomomi Kobayashi
  • Patent number: 10617643
    Abstract: This disclosure relates to polymersomes comprising a crosslinked polymer and their use as drug delivery vehicles. Specifically, polymersomes comprising a polymer of Formula I: wherein each R is independently C1-6 alkyl; and n is an integer between 1 and 50.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 14, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Xifeng Liu, Michael J. Yaszemski, Lichun Lu
  • Patent number: 10618881
    Abstract: Methods that include acylating an aromatic containing compound by reacting the aromatic containing compound with an anhydride containing compound to form an acylated aromatic containing compound.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: April 14, 2020
    Assignees: Regents of the University of Minnesota, University of Delaware
    Inventors: Dae Sung Park, Christoph Krumm, Maura Koehle, Kristeen Joseph, Dionisos G. Vlachos, Raul F. Lobo, Paul J. Dauenhauer
  • Patent number: 10618878
    Abstract: A method of reducing an aromatic ring under relatively mild condition using sub-nano particles of a transition metal supported on super paramagnetic iron oxide nanoparticles (SPIONs). The catalyst is efficient for catalyzing the reduction of both carbocyclic and heterocyclic compound. In compound comprising both carbocyclic and heterocyclic aromatic rings, the catalyst displays high regioselectivity for the heterocyclic ring.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: April 14, 2020
    Assignee: King Fahd University of Petroleum and Minerals
    Inventors: M. Nasiruzzaman Shaikh, Zain H. Yamani
  • Patent number: 10610520
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: April 7, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shuhei Ikeda, Hideyuki Sugiyama, Jumpei Aida, Hidekazu Tokuhara, Tomohiro Okawa, Yuya Oguro, Minoru Nakamura, Masataka Murakami
  • Patent number: 10611744
    Abstract: A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: April 7, 2020
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Deepak Phadke, Natalie M. Platt, Ravi K. Pandrapragada
  • Patent number: 10604529
    Abstract: The invention discloses a type of fused imidazole compound, preparation method and application thereof. The structure of the compound is shown in general formula I. The definition of each group therein is as described in the specification. These compounds are capable of selectively inhibiting indoleamine 2,3-dioxygenase (IDO). The compounds can act as an IDO inhibitor for treating and/or preventing a disease having a pathological feature with IDO-mediated tryptophan metabolic pathways, for example, cancer, eye disease, autoimmune disease, psychological disorder, depression symptom, anxiety disorder and other diseases.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: March 31, 2020
    Assignee: SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.
    Inventors: Jindi Yu, Xianping Lu, Zhibin Li, Lijun Xin, Jiangfei Zhu, Chao Fu
  • Patent number: 10597365
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: March 24, 2020
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
  • Patent number: 10590109
    Abstract: The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the same, a preparation method thereof, and use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The compound is a heterocyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, prodrug, solvent compound, polymorph, isomer or stable isotopic derivative thereof. The present invention further relates to use of the compound for the treatment or prevention of related diseases which are FGFR-mediated such as cancer, and a method for applying the compound to treat said diseases.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 17, 2020
    Assignee: Nanjing InnoCare Pharma Tech Co., Ltd.
    Inventors: Norman Xianglong Kong, Chao Zhou, Zhixiang Zheng
  • Patent number: 10590107
    Abstract: The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising a compound of formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: March 17, 2020
    Assignee: Theravance Respiratory Company, LLC
    Inventors: Adam D. Hughes, Daniel Byun, Yan Chen, Melissa Fleury, John R. Jacobsen, Eric Stangeland, Richard D. Wilson, Rose Yen
  • Patent number: 10584110
    Abstract: The invention relates to compounds of formula IA and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: March 10, 2020
    Assignee: Purdue Pharma L.P.
    Inventor: Laykea Tafesse
  • Patent number: 10570109
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: February 25, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Patent number: 10562913
    Abstract: Compounds for use as sensitizer dyes in dye-sensitized solar cells.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: February 18, 2020
    Assignee: University of Mississippi
    Inventors: Jared Delcamp, Aron Huckaba
  • Patent number: 10562885
    Abstract: A compound represented by formula (5) can be produced by simultaneously and separately adding a compound represented by formula (4) and methanesulfonyl chloride to a compound represented by formula (3) and a compound represented by formula (6) having excellent control efficacies against pests can be produced by subjecting the compound represented by formula (5) to intramolecular condensation in the presence of an acid.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: February 18, 2020
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Tomohiko Inui, Masaya Tanimoto
  • Patent number: 10562845
    Abstract: A compound represented by Chemical Formula 1 according to the present invention can coordinate with metal ions to form a bidirectional or multidirectional metal-organic hybrid structure. Thus, the present invention can synthesize various ligands using amine-aldehyde condensation, and synthesize metal-organic materials using the same.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: February 18, 2020
    Assignees: LG CHEM, LTD., Seoul National University R&DB Foundation
    Inventors: Dongwhan Lee, Jung Hwan Kim, Won Jong Kwon, Yong Jin Bae
  • Patent number: 10548877
    Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: February 4, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masaki Ogino, Eiji Kimura, Shinkichi Suzuki, Kouji Fuji, Tomohiro Ohashi, Makoto Fushimi, Kei Masuda, Tatsuki Koike, Takeshi Wakabayashi, Jinichi Yonemori, Masami Yamada
  • Patent number: 10550094
    Abstract: The invention relates to compounds having general formula (I): where R?H, CH2—OH, CH2—O—CO—CH3, CH2—O—CO-Ph (Ph=phenyl) R??H, CH2—O—CO—CH3, CH2—O—CO-Ph (Ph=phenyl) Ar=phenyl, 3-methoxy-4-hydroxy phenyl, 2-furyl. These are compounds having antioxidant activity against free radicals together with anti-inflammatory activity, the compounds being useful as active ingredients for the preparation of pharmaceutical dermatological or cosmetic compositions for skin care.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: February 4, 2020
    Assignee: Giuliana S.P.A.
    Inventors: Giammaria Giuliani, Anna Benedusi, Barbara Marzani, Sergio Baroni